Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using a product containing dutasteride and tamsulosin for hair loss. Users discuss separating the components and potential side effects like frequent urination and changes in libido.

The user is considering adding Pyrilutamide or Alfatradiol as a topical treatment for hair loss after oral Finasteride and Dutasteride became less effective. Other users suggest Pyrilutamide for its safety profile, while one user shares positive experiences with RU58841 for reducing scalp itch and improving hairline.

A user is considering a solution with 7% minoxidil, 0.25% finasteride, and 0.0125% tretinoin for hair loss, as suggested by their dermatologist. Other users share their experiences with similar treatments, noting mixed results and suggesting stronger alternatives like dutasteride.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

User started Finasteride for hair loss and uses Toppik to cover bald spots. They wonder if Toppik's keratin fibers will block follicles and affect hair regrowth.

The use of PRP to treat hair loss and its potential effectiveness when combined with 5 alpha reductase blockers such as Minoxidil or Finasteride.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

OP asked if Alfatradiol 0.1% can maintain hair after a transplant. Responses suggest using stronger treatments like finasteride or micro-dosing oral finasteride instead.

A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.

The user discusses their experience with diffuse unpatterned alopecia and acquired progressive hair kinkering, noting improvements with treatments including biotin, pantothenic acid, finasteride, ketoconazole, and zinc pyrithione shampoo. They report thicker, healthier hair and improved scalp condition, attributing success mainly to biotin, pantothenic acid, and finasteride.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

27F with androgenic alopecia since 17 seeks treatment. Tried spironolactone, caused low blood pressure; believes finasteride is safer and wants to try it.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

OP used oral minoxidil (2.5 mg) and dutasteride (0.5 mg) for 12 months with successful hair regrowth. Consistency in treatment is emphasized, and switching from finasteride to dutasteride is suggested for better results.

The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.

RU58841 and tretinoin are discussed for better absorption in hair loss treatment. The effectiveness of tretinoin with minoxidil is debated.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

A user named Medical_Opinion8120, a 23-year-old female, is experiencing hair loss potentially due to a past accutane course. She has tried minoxidil without success and is currently taking iron and zinc supplements.

A user is seeking information on clinics in Toronto offering dutasteride mesotherapy as an alternative to oral dutasteride while trying to conceive. They are looking for recommendations and information.

Tae147 has shared results of using pyrilutamide, a 5% concentration topical solution applied twice daily, in combination with minoxidil, to reduce scalp itchiness and hair shedding. Other users have shared their experiences with the treatment, as well as questions about its availability on the market.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

The conversation discusses the use of Finastopic, a carrier for finasteride solutions by Isdin, and compares it to a standard propylene glycol (PG) solution. The user was prescribed a 1% finasteride solution using Finastopic and has been using a self-compounded 0.025% topical finasteride with minoxidil.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Using retinol with minoxidil may not be as effective as tretinoin, but retinaldehyde or adapalene could be alternatives. A micro-roller with minoxidil is suggested for better results.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.